Clinical trials: Alzheimer Disease 5
Norovirus Infection
Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines
VXA-NVV-103 is a phase 1B Randomized, Double-Blind, Placebo-Controlled, Multi-Center Safety and Immunogenicity Study of Adenoviral-vector Based Oral Norovirus Vaccines Expressing GI.1 or GII.4 VP1 with Monovalent or Bivalent…
- Trial name
- VXA-NVV-103 (NCT03897309)
- Testing
- VXA-G1.1-NN, VXA-G2.4-NS
- Where
- United States
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Vaxart
Cancer
QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer
The purpose of this study is to determine whether ETBX-021 is safe and effective in the treatment of unresectable locally advanced or metastatic HER2-low-expressing breast cancer.
- Trial name
- NCT02751528
- Testing
- ETBX-021
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- NantBioScience, Inc.
COVID-19
Heterologous Boost Immunization with Ad5-nCoV After Three-dose Priming with an Inactivated SARS-CoV-2 Vaccine
This is an open-label, randomized, parallel-controlled clinical trial to evaluate the safety and immunogenicity of heterologous prime-boost immunization with an aerosolized (Ad5-nCoV-IH) or intramuscular (Ad5-nCoV-IM) Ad5-nCoV…
- Trial name
- NCT05303584
- Testing
- Ad5-nCoV-IH, Ad5-nCoV-IM, CoronaVac
- Where
- China
- Volunteers
- 362 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
COVID-19
Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine
This is a randomized, observer-blind, placebo-controlled study, for evaluation of safety and immunogenicity of heterologous prime-boost immunization of recombinant COVID-19 vaccine (adenovirus type-5 vector) and RBD-based protein…
- Trial name
- NCT04833101
- Testing
- recombinant Ad5 vectored COVID-19 vaccine, RBD-based protein subunit vaccine (ZF2001) against COVID-19, trivalent split influenza vaccine
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Alzheimer's Disease
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44
The core study assessed the efficacy of a higher dose of rivastigmine 13.3 mg/24 h transdermally (15 cm^2 patch) compared to a lower dose of the rivastigmine 4.6 mg/24 h transdermally (5 cm^2 patch) in patients with Severe…
- Trial name
- ACTION (NCT00948766)
- Testing
- Rivastigmine 4.6 mg/24 h (5 cm^2), Rivastigmine 9.5 mg/24 h (10 cm^2), Rivastigmine 13.3 mg/24 h (15 cm^2)
- Where
- 95 sites in United States, Puerto Rico
- Volunteers
- 716 people
- Sponsor
- Novartis
Depressive Symptoms, Depression
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
This open-label pilot study examines whether the hallucinogenic drug, psilocybin, given under supportive conditions, is safe and effective for depression in people with Mild Cognitive Impairment (MCI) or early Alzheimer's Disease…
- Conditions
- Depressive Symptoms, Depression, Alzheimer Disease, Mild Cognitive Impairment
- Trial name
- NCT04123314
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Johns Hopkins University
Colon Cancer
Phase I Study of Ad5-hGCC (Human Guanylyl Cyclase C)-PADRE in Stage I/II Colon Cancer
The purpose of this study is to determine the safety, tolerability and ability to stimulate hGCC-specific antibody and killer T cell immune responses of an Ad5-hGCC-PADRE vaccine in stage I and stage II Caucasian and African…
- Trial name
- NCT01972737
- Testing
- Ad5-hGCC-PADRE vaccine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Patients Aged 65-85 (Both Included), Diagnosed of Mild Cognitive Impairment
Diabetes as an Accelerator of Cognitive Impairment and Alzheimer's Disease
This randomized controlled trial is aimed at studying the effects of an eHealth intervention on improving metabolic control and other cardiovascular risk factors (obesity, lipidic profile and hypertension) as the approach to…
- Conditions
- Patients Aged 65-85 (Both Included), Diagnosed of Mild Cognitive Impairment, Diagnosed of Type 2 Diabetes in Active Treatment (Hypoglycemic Agents) for a Period ≥5 Years
- Trial name
- DIALCAT (NCT03578991)
- Testing
- Smart pillbox, Interactive digital platform
- Where
- 8 sites in Spain
- Volunteers
- 54 people
- Sponsor
- Parc Sanitari Pere Virgili
Ebola Virus Disease
A Phase I Trial to Evaluate Ad5-EBOV in Healthy Adult Africans in China.
This is a single center, open, dose-escalation phase 1 clinical trial. This study will determine the safety and side-effect profile, and immunogenicity of an investigational Ad5-EBOV vaccine in Healthy Adult Africans aged between…
- Trial name
- NCT02401373
- Testing
- Ad5-EBOV
- Where
- China
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Zhejiang University
Colorectal Cancer, Lung Cancer
QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA
The purpose of this study is to find out what effects (good and bad) that a cancer vaccine has on you and your cancer. The cancer vaccine is called Ad5 [E1-, E2b-]-CEA(6D)or ETBX-011 and is made by Etubics.
- Conditions
- Colorectal Cancer, Lung Cancer, Breast Cancer, Prostate Cancer
- Trial name
- NCT01147965
- Testing
- Ad5 CEA Vaccine
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- NantCell, Inc.
COVID-19
A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector)
This is a phase II, randomised, double-blinded and placebo-controlled clinical trial in healthy adults above 18 years of age. This clinical trial is designed to evaluate the immunogenicity and safety of Ad5-nCoV which encodes for…
- Trial name
- CTII-nCoV (NCT04341389)
- Testing
- Recombinant novel coronavirus vaccine (Adenovirus type 5 vector)
- Where
- China
- Volunteers
- 508 people, healthy volunteers welcome
- Sponsor
- Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China
Dementia Alzheimer's Type
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
Primary Objective: To demonstrate the efficacy of at least one dose of SAR110894 (H3 receptor antagonist) in comparison to placebo on cognitive performance in patients with mild to moderate Alzheimer's disease (AD) while on…
- Trial name
- NCT01266525
- Testing
- SAR110894, Donepezil
- Where
- 82 sites in United States, Australia and 7 more
- Volunteers
- 291 people
- Sponsor
- Sanofi
Covid19
Clinical Trial of the Immunogenicity, Safety, and Efficacy of the Gam-COVID-Vac Vaccine Against COVID-19 in Venezuela
Randomized, double-blind, placebo controlled clinical trial of immunogenicity, safety and efficacy of the Gam-COVID-Vac combined vector vaccine against the SARS-CoV-2-induced coronavirus infection in adults.
- Trial name
- VENEZUELA (NCT04642339)
- Testing
- Gam-COVID-Vac
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Alzheimer Disease
A Multi-Center, Randomized, Double-Blind, Parallel Group Study With 3 Groups Receiving Placebo, 5 mg of E2020 and 10 mg of E2020
To evaluate the dose-response efficacy of E2020 (5 mg/day and 10 mg/day) versus placebo and verify superiority of E2020 to placebo in patients with severe AD using CIBIC-plus* and SIB** as the primary efficacy measures.
- Trial name
- NCT00165659
- Testing
- DONEPEZIL HYDROCHLORIDE
- Where
- 65 sites in Japan
- Sponsor
- Eisai Limited
Ebola Virus Disease
A Booster Dose of Ad5-EBOV in Healthy Adults After Primary Immunization
Since its first outbreak occurred in 1976, Zaire Ebola virus have been associated with 14 outbreaks reported up to 2014. The Zaire Ebola virus in 2014 causing the most serious outbreak was considered to be a new epidemic strain…
- Trial name
- NCT02533791
- Testing
- 4×10^10vp/1ml Ebola Zaire vaccine (Ad5-EBOV), 1.6×10^11vp/2ml Ebola Zaire vaccine (Ad5-EBOV)
- Where
- China
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
COVID-19
Clinical Evaluation for Batch Consistency of Ad5-nCoV in Chinese Healthy Adults
This is a randomized, double-blind, parallel-controlled, equivalence trial, for evaluation of safety and immunogenicity, and batch-to-batch consistency of a recombinant adenovirus type-5-vectored Covid-19 vaccine Convidecia in…
- Trial name
- NCT05313646
- Testing
- batch 1 of Ad5-nCoV, batch 2 of Ad5-nCoV, batch 3 of Ad5-nCoV
- Where
- China
- Volunteers
- 1,050 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
COVID-19
Study on Sequential Immunization of Inactivated SARS-CoV-2 Vaccine and Recombinant SARS-CoV-2 Vaccine (Ad5 Vector)
This is a randomized, observer-blind, parallel-controlled study, for evaluation of safety and immunogenicity of sequential immunization of a recombinant SARS-CoV-2 vaccine (adenovirus type 5 vector) in Chinese healthy adults aged…
- Trial name
- NCT04892459
- Testing
- Recombinant SARS-CoV-2 Ad5 vectored vaccine, Inactive SARS-CoV-2 vaccine (Vero cell)
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Ebola Virus Disease
A Phase I Clinical Trial to Evaluate the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults.
Since its first outbreak occurred in 1976, Zaire Ebola virus have been associated with 14 outbreaks reported up to 2014. The Zaire Ebola virus in 2014 causing the most serious outbreak was considered to be a new epidemic strain…
- Trial name
- NCT02326194
- Testing
- Low dose Ebola Zaire vaccine (Ad5-EBOV), High dose Ebola Zaire vaccine (Ad5-EBOV)
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Covid19
Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19
This study is a phase III clinical trial to evaluate efficacy, reactogenicity and safety of the vaccine Ad5-nCoV compared with placebo in volunteers at the age from 18 to 85 years，with the randomized, double-blind design
- Trial name
- NCT04540419
- Testing
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- Where
- 7 sites in Russia
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- NPO Petrovax
Alzheimer Type Dementia
An Efficacy and Safety Study of INM-176 for the Treatment of Patients With Alzheimer Type Dementia
The purpose of this study is to evaluate the efficacy and safety of two fixed dose (1200mg/day, 1600mg/day) of INM-176 (a drug of treating dementia) comparing with donepezil for treatment for patients with Alzheimer type dementia.
- Trial name
- NCT01245530
- Testing
- Aricept, INM-176
- Where
- South Korea
- Volunteers
- 280 people
- Sponsor
- Whanin Pharmaceutical Company